Epigenetic therapy for breast cancer |
| |
Authors: | Cai Feng-Feng Kohler Corina Zhang Bei Wang Ming-Hong Chen Wei-Jie Zhong Xiao-Yan |
| |
Affiliation: | Laboratory for Gynecological Oncology, Department of Biomedicine, Women's Hospital, University of Basel, Hebelstrasse 20, Room 420, Basel, CH 4031, Switzerland; E-Mails: fcai@uhbs.ch (F.-F.C.); kohlerc@uhbs.ch (C.K.); zhangb@uhbs.ch (B.Z.); wchen@uhbs.ch (W.-J.C.). |
| |
Abstract: | Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. Some DNA methylation inhibitors and histone deacetylation inhibitors are approved by the US Food and Drug Administration as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer. |
| |
Keywords: | breast cancer epigenetic therapy DNA methylation inhibitors Histone deacetylation inhibitors |
本文献已被 PubMed 等数据库收录! |
|